18F-FDG PET/CT and melanoma

Staging, immune modulation and mutation-targeted therapy assessment, and prognosis

Powell Perng, Charles Marcus, Rathan M. Subramaniam

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalAmerican Journal of Roentgenology
Volume205
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Fluorodeoxyglucose F18
Melanoma
Mutation
Signal Transduction
Cell Death
Therapeutics
Monoclonal Antibodies
Ligands
Proteins

Keywords

  • FDG PET/CT
  • Immune modulation therapy
  • Melanoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG PET/CT and melanoma : Staging, immune modulation and mutation-targeted therapy assessment, and prognosis. / Perng, Powell; Marcus, Charles; Subramaniam, Rathan M.

In: American Journal of Roentgenology, Vol. 205, No. 2, 01.01.2015, p. 259-270.

Research output: Contribution to journalReview article

@article{ecdd861d356744eb8513ad361fd20958,
title = "18F-FDG PET/CT and melanoma: Staging, immune modulation and mutation-targeted therapy assessment, and prognosis",
abstract = "OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.",
keywords = "FDG PET/CT, Immune modulation therapy, Melanoma",
author = "Powell Perng and Charles Marcus and Subramaniam, {Rathan M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2214/AJR.14.13575",
language = "English (US)",
volume = "205",
pages = "259--270",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

TY - JOUR

T1 - 18F-FDG PET/CT and melanoma

T2 - Staging, immune modulation and mutation-targeted therapy assessment, and prognosis

AU - Perng, Powell

AU - Marcus, Charles

AU - Subramaniam, Rathan M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

AB - OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

KW - FDG PET/CT

KW - Immune modulation therapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84938699299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938699299&partnerID=8YFLogxK

U2 - 10.2214/AJR.14.13575

DO - 10.2214/AJR.14.13575

M3 - Review article

VL - 205

SP - 259

EP - 270

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 2

ER -